देश: ऑस्ट्रेलिया
भाषा: अंग्रेज़ी
स्रोत: Department of Health (Therapeutic Goods Administration)
linaclotide, Quantity: 0.145 mg
Abbvie Pty Ltd
Capsule, hard
Excipient Ingredients: microcrystalline cellulose; calcium chloride dihydrate; leucine; hypromellose; titanium dioxide; potable water; Gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; Shellac; sulfuric acid
Oral
4, 30
(S4) Prescription Only Medicine
CONSTELLA is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (IBS-C) and ? chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.
Visual Identification: White to off-white opaque body and cap, size '3' hard capsules with "FL 145" printed in grey ink on the cap.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 23 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2019-06-18